Emerging Company Profile
Bluejay: combining HBV therapies to reach a functional cure
Emerging Company Profile: Led by Keting Chu, Bluejay is advancing HBV assets in-licensed from Novartis
Led by Keting Chu, Bluejay is advancing a trio of HBV assets in-licensed from Novartis after the pharma exited antiviral research.
Bluejay is applying a combination of therapies in-licensed from Novartis with an aim to cure chronic HBV by reducing viral surface antigen in both the liver and blood.